Skip to main content
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2022 Dec 19;23(1):161. doi: 10.1186/s10194-022-01530-9

Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Andreas R Gantenbein 1,, Reto Agosti 2, Christian P Kamm 3,4, Gunther Landmann 5, Niklaus Meier 6, Gabriele Susanne Merki-Feld 7, Jens A Petersen 8, Heiko Pohl 9, Philippe Ryvlin 10, Christoph J Schankin 3, Dragana Viceic 11, Chiara Zecca 12,13, Elisabeth Schäfer 1, Ina Meyer 14, Michael E Arzt 14
PMCID: PMC9764682  PMID: 36536271

Correction: J Headache Pain 23, 142 (2022)

https://doi.org/10.1186/s10194-022-01515-8

Following publication of the original article [1], the author group has identified an error in Fig. 1. The correct figure is given below.

Fig. 1.

Fig. 1

Study design and visit schedule. mo: month; V: visit

The original article [1] has been corrected.

Reference

  • 1.Gantenbein AR, Agosti R, Kamm CP, et al. Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results. J Headache Pain. 2022;23:142. doi: 10.1186/s10194-022-01515-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES